Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference
09/01/2022 - 08:30 AM
SAN DIEGO Sept. 1, 2022 Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the 2022 Wells Fargo Healthcare Conference being held in Boston, MA on September 7-9, 2022 .
Details for the presentation are as follows:
Event:
2022 Wells Fargo Healthcare Conference
Format:
Presentation and 1x1 Meetings
Presentation Date:
Thursday, September 8, 2022
Presentation Time:
5:35 a.m. PT / 8:35 a.m. ET
A live audio webcast of the presentation will be available in the Investor Relations section of the Company's website. Replays of the audio webcast will be available for 90 days following the conference.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 600,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® , TLANDO™ and NOCDURNA® and partnered commercial products and ongoing product development programs with industry leading pharmaceutical companies including Teva Pharmaceutical, Covis Pharma, Pfizer and Idorsia Pharmaceuticals.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
Contacts: Tram Buitbui@antarespharma.com
Dawn Schottlandt / Claudia StyslingerHalozyme@argotpartners.com
https://www.prnewswire.com/news-releases/halozyme-to-participate-in-the-2022-wells-fargo-healthcare-conference-301616387.html
SOURCE Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc.
HALO Rankings
#3871 Ranked by Stock Gains
HALO Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
San Diego
About HALO
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
